Veloxis Pharmaceuticals is a biopharmaceutical company that identifies, develops, and commercializes products used in transplantation and adjacent therapies. The company's patented delivery technology, MeltDose, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis's lead product candidate is Envarsus XR, a once-daily tablet version of tacrolimus, used to aid in the prophylaxis of organ rejection in transplant recipients.